Achillion Pharmaceuticals (ACHN) 10.11 $ACHN
Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD)
GlobeNewswire - Sat Nov 08, 8:01AM CST
- Achillion Achieves 100% SVR12 in Eight-Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study"
Including Nine of 12 Patients With Viral Loads Higher Than 6 Million IU/ml at Baseline -
ACHN: 10.11 (-0.15)
Achillion Announces Upcoming Poster Presentations Discussing Novel Oral Complement Factor D Inhibitor Platform at the 56th Annual Meeting of the American Society of Hematology
GlobeNewswire - Thu Nov 06, 8:45AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that two abstracts are scheduled for presentation at the 56 Annual Meeting of the American Society of Hematology (ASH) in San Francisco, CA, December 6 - 9. The abstracts are now available at http://www.hematology.org/Annual-Meeting/.
ACHN: 10.11 (-0.15)
Why Achillion Pharmaceuticals, Inc. Stock Launched 18% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 06, 8:40AM CST
ACHN data by YCharts What: Shares of Achillion Pharmaceuticals , a clinical-stage biopharmaceutical company focused on developing therapies to treat hepatitis C and other chronic bacterial infections, launched higher by 18% during the month...
GILD: 106.45 (-0.49), ACHN: 10.11 (-0.15)
Achillion Pharmaceuticals Slumps: ACHN Plunges 15.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:34AM CST
Achillion Pharmaceuticals (ACHN) fell nearly 16% in the last trading session amid huge volumes, reversing its recent trend, as the stock is now up nearly 3% in the past one month.
AGEN: 3.02 (-0.03), HSKA: 15.90 (+0.71), ACHN: 10.11 (-0.15), AMAG: 34.95 (+0.83)
Nasdaq stocks posting largest percentage decreases
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
BRDR: 7.00 (-0.04), ALIM: 5.06 (-0.04), ACHN: 10.11 (-0.15), FNHC: 26.14 (+0.04), ARCP: 8.79 (+0.15), CKEC: 27.90 (-0.17), JAXB: 11.69 (+1.08), PCLN: 1,094.61 (-3.14), TESO: 16.06 (+0.33)
Most active Nasdaq-traded stocks
AP - Tue Nov 04, 12:22PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
FB: 75.60 (+0.34), PLUG: 5.30 (+0.18), NYMX: 0.75 (+0.04), INTC: 33.58 (-0.24), FOX: 33.24 (-0.69), SAPE: 24.67 (+0.03), GERN: 2.33 (-0.07), ACHN: 10.11 (-0.15), FOXA: 34.61 (-0.70), ODP: 6.50 (+0.13), ARCP: 8.79 (+0.15), MSFT: 48.68 (-0.02), GRPN: 7.50 (-0.02), AAPL: 109.01 (+0.31)
Achillion Pharmaceuticals (ACHN) Stock Plummets on Lack of ACH-3422 Data in Quarterly Earnings
at The Street - Tue Nov 04, 10:31AM CST
Shares of Achillion Pharmaceuticals (ACHN) plunged in morning trading Tuesday after the company did not provide any data on its hepatitis C drug ACH-3422.
ACHN: 10.11 (-0.15)
Biotech Equities Coverage - Achillion Pharma, Sarepta Therapeutics, Alnylam Pharma, Incyte, and Cytori Therapeutics
PR Newswire - Tue Nov 04, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Incyte Corporation (NASDAQ: INCY), and Cytori Therapeutics Inc. (NASDAQ: CYTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, November 03, 2014, the NASDAQ Composite ended at 4,638.91, up 0.18%, the Dow Jones Industrial Average edged 0.14% lower to finish the day at 17,366.24, and the S&P 500 closed at 2,017.81, down 0.01%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index also advancing 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ALNY: 95.84 (+2.93), CYTX: 0.43 (-0.07), ACHN: 10.11 (-0.15), INCY: 69.32 (+0.92), SRPT: 16.12 (-0.14)
Achillion beats 3Q profit forecasts
Automated Insights - Tue Nov 04, 5:36AM CST
NEW HAVEN, Conn. (AP) _ Achillion Pharmaceuticals Inc. (ACHN) on Tuesday reported a loss of $15.7 million in its third quarter.
ACHN: 10.11 (-0.15)
Achillion Reports Third Quarter and Nine Month 2014 Financial Results
GlobeNewswire - Tue Nov 04, 5:30AM CST
- Hepatitis C development program remains on track to initiate all-oral ribavirin-free regimens with ACH-3422, ACH-3102 and sovaprevir for HCV in 2015 -
ACHN: 10.11 (-0.15)
Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 106.45 (-0.49), CLVS: 58.31 (-0.26), ARWR: 6.06 (-0.24), ACHN: 10.11 (-0.15), MRK: 59.34 (+0.08), RTRX: 10.38 (+0.29), RGLS: 22.08 (+2.42), EPZM: 23.75 (+0.19), AGIO: 72.06 (-11.03), RMTI: 10.55 (+1.22), ARNA: 4.26 (+0.01), KERX: 16.73 (-0.47)
Critical Alerts For NetSuite, CVS Caremark, Netflix, VeriFone Systems and Achillion Pharmaceuticals Released By InvestorsObserver
PR Newswire - Mon Oct 27, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for N, CVS, NFLX, PAY and ACHN.
NFLX: 384.16 (+0.86), ACHN: 10.11 (-0.15), CVS: 88.38 (-0.05), N: 109.08 (+1.13), PAY: 36.56 (-0.42)
Speculating on Achillion's Boom-or-Bust Hep C Drug Study Results
at The Street - Wed Oct 22, 7:39AM CDT
My question about Achillion and ACH-3422 question sparked a robust Twitter debate, which I've reproduced below with some additional comments and explanatory notes.
GILD: 106.45 (-0.49), ACHN: 10.11 (-0.15), MRK: 59.34 (+0.08), ABBV: 61.50 (-1.21)
Upcoming Earnings, Presentation of Clinical Data, Dividends, and Technical Updates - Research Reports on Achillion, KB Home, Hovnanian, QEP Resources and Fortune Brands
PR Newswire - Fri Oct 17, 8:30AM CDT
Today, Analysts Review released its research reports regarding Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), KB Home (NYSE: KBH), Hovnanian Enterprises Inc. (NYSE: HOV), QEP Resources, Inc. (NYSE: QEP) and Fortune Brands Home & Security, Inc. (NYSE: FBHS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7277-100free.
QEP: 25.87 (+0.32), FBHS: 42.80 (+0.17), ACHN: 10.11 (-0.15), KBH: 16.34 (+0.36), HOV: 3.77 (+0.03)
November 28th Options Now Available For Achillion Pharmaceuticals (ACHN)
DividendChannel.com - Thu Oct 09, 10:04AM CDT
Investors in Achillion Pharmaceuticals Inc. saw new options become available today, for the November 28th expiration.
ACHN: 10.11 (-0.15)
Achillion to Present Updated Clinical HCV Data on ACH-3102 and Preclinical Profile of ACH-3422 at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
GlobeNewswire - Wed Oct 08, 9:23AM CDT
- Late breaker poster presentation will feature updated SVR results from the Phase 2 trial of ACH-3102, NS5A inhibitor, plus sofosbuvir for the eight-week treatment of genotype 1 HCV -
ACHN: 10.11 (-0.15)
Biotech Stock Mailbag: Seattle Genetics, Achillion, Catalyst Pharma
at The Street - Fri Oct 03, 8:41AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
JNJ: 108.20 (-0.81), SGEN: 36.05 (+1.20), CPRX: 2.73 (-0.09), ACHN: 10.11 (-0.15), SNSS: 1.63 (-0.05), BMY: 58.32 (-0.14)
Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD)
GlobeNewswire - Sat Nov 08, 8:01AM CST
- Achillion Achieves 100% SVR12 in Eight-Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study"
Including Nine of 12 Patients With Viral Loads Higher Than 6 Million IU/ml at Baseline - ACHN: 10.11 (-0.15)
Achillion Announces Upcoming Poster Presentations Discussing Novel Oral Complement Factor D Inhibitor Platform at the 56th Annual Meeting of the American Society of Hematology
GlobeNewswire - Thu Nov 06, 8:45AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that two abstracts are scheduled for presentation at the 56 Annual Meeting of the American Society of Hematology (ASH) in San Francisco, CA, December 6 - 9. The abstracts are now available at http://www.hematology.org/Annual-Meeting/.
ACHN: 10.11 (-0.15)
Why Achillion Pharmaceuticals, Inc. Stock Launched 18% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 06, 8:40AM CST
ACHN data by YCharts What: Shares of Achillion Pharmaceuticals , a clinical-stage biopharmaceutical company focused on developing therapies to treat hepatitis C and other chronic bacterial infections, launched higher by 18% during the month...
GILD: 106.45 (-0.49), ACHN: 10.11 (-0.15)
Achillion Pharmaceuticals Slumps: ACHN Plunges 15.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:34AM CST
Achillion Pharmaceuticals (ACHN) fell nearly 16% in the last trading session amid huge volumes, reversing its recent trend, as the stock is now up nearly 3% in the past one month.
AGEN: 3.02 (-0.03), HSKA: 15.90 (+0.71), ACHN: 10.11 (-0.15), AMAG: 34.95 (+0.83)
Nasdaq stocks posting largest percentage decreases
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
BRDR: 7.00 (-0.04), ALIM: 5.06 (-0.04), ACHN: 10.11 (-0.15), FNHC: 26.14 (+0.04), ARCP: 8.79 (+0.15), CKEC: 27.90 (-0.17), JAXB: 11.69 (+1.08), PCLN: 1,094.61 (-3.14), TESO: 16.06 (+0.33)
Most active Nasdaq-traded stocks
AP - Tue Nov 04, 12:22PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
FB: 75.60 (+0.34), PLUG: 5.30 (+0.18), NYMX: 0.75 (+0.04), INTC: 33.58 (-0.24), FOX: 33.24 (-0.69), SAPE: 24.67 (+0.03), GERN: 2.33 (-0.07), ACHN: 10.11 (-0.15), FOXA: 34.61 (-0.70), ODP: 6.50 (+0.13), ARCP: 8.79 (+0.15), MSFT: 48.68 (-0.02), GRPN: 7.50 (-0.02), AAPL: 109.01 (+0.31)
Achillion Pharmaceuticals (ACHN) Stock Plummets on Lack of ACH-3422 Data in Quarterly Earnings
at The Street - Tue Nov 04, 10:31AM CST
Shares of Achillion Pharmaceuticals (ACHN) plunged in morning trading Tuesday after the company did not provide any data on its hepatitis C drug ACH-3422.
ACHN: 10.11 (-0.15)
Biotech Equities Coverage - Achillion Pharma, Sarepta Therapeutics, Alnylam Pharma, Incyte, and Cytori Therapeutics
PR Newswire - Tue Nov 04, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Incyte Corporation (NASDAQ: INCY), and Cytori Therapeutics Inc. (NASDAQ: CYTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, November 03, 2014, the NASDAQ Composite ended at 4,638.91, up 0.18%, the Dow Jones Industrial Average edged 0.14% lower to finish the day at 17,366.24, and the S&P 500 closed at 2,017.81, down 0.01%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index also advancing 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ALNY: 95.84 (+2.93), CYTX: 0.43 (-0.07), ACHN: 10.11 (-0.15), INCY: 69.32 (+0.92), SRPT: 16.12 (-0.14)
Achillion beats 3Q profit forecasts
Automated Insights - Tue Nov 04, 5:36AM CST
NEW HAVEN, Conn. (AP) _ Achillion Pharmaceuticals Inc. (ACHN) on Tuesday reported a loss of $15.7 million in its third quarter.
ACHN: 10.11 (-0.15)
Achillion Reports Third Quarter and Nine Month 2014 Financial Results
GlobeNewswire - Tue Nov 04, 5:30AM CST
- Hepatitis C development program remains on track to initiate all-oral ribavirin-free regimens with ACH-3422, ACH-3102 and sovaprevir for HCV in 2015 -
ACHN: 10.11 (-0.15)
Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 106.45 (-0.49), CLVS: 58.31 (-0.26), ARWR: 6.06 (-0.24), ACHN: 10.11 (-0.15), MRK: 59.34 (+0.08), RTRX: 10.38 (+0.29), RGLS: 22.08 (+2.42), EPZM: 23.75 (+0.19), AGIO: 72.06 (-11.03), RMTI: 10.55 (+1.22), ARNA: 4.26 (+0.01), KERX: 16.73 (-0.47)
Critical Alerts For NetSuite, CVS Caremark, Netflix, VeriFone Systems and Achillion Pharmaceuticals Released By InvestorsObserver
PR Newswire - Mon Oct 27, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for N, CVS, NFLX, PAY and ACHN.
NFLX: 384.16 (+0.86), ACHN: 10.11 (-0.15), CVS: 88.38 (-0.05), N: 109.08 (+1.13), PAY: 36.56 (-0.42)
Speculating on Achillion's Boom-or-Bust Hep C Drug Study Results
at The Street - Wed Oct 22, 7:39AM CDT
My question about Achillion and ACH-3422 question sparked a robust Twitter debate, which I've reproduced below with some additional comments and explanatory notes.
GILD: 106.45 (-0.49), ACHN: 10.11 (-0.15), MRK: 59.34 (+0.08), ABBV: 61.50 (-1.21)
Upcoming Earnings, Presentation of Clinical Data, Dividends, and Technical Updates - Research Reports on Achillion, KB Home, Hovnanian, QEP Resources and Fortune Brands
PR Newswire - Fri Oct 17, 8:30AM CDT
Today, Analysts Review released its research reports regarding Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), KB Home (NYSE: KBH), Hovnanian Enterprises Inc. (NYSE: HOV), QEP Resources, Inc. (NYSE: QEP) and Fortune Brands Home & Security, Inc. (NYSE: FBHS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7277-100free.
QEP: 25.87 (+0.32), FBHS: 42.80 (+0.17), ACHN: 10.11 (-0.15), KBH: 16.34 (+0.36), HOV: 3.77 (+0.03)
November 28th Options Now Available For Achillion Pharmaceuticals (ACHN)
DividendChannel.com - Thu Oct 09, 10:04AM CDT
Investors in Achillion Pharmaceuticals Inc. saw new options become available today, for the November 28th expiration.
ACHN: 10.11 (-0.15)
Achillion to Present Updated Clinical HCV Data on ACH-3102 and Preclinical Profile of ACH-3422 at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
GlobeNewswire - Wed Oct 08, 9:23AM CDT
- Late breaker poster presentation will feature updated SVR results from the Phase 2 trial of ACH-3102, NS5A inhibitor, plus sofosbuvir for the eight-week treatment of genotype 1 HCV -
ACHN: 10.11 (-0.15)
Biotech Stock Mailbag: Seattle Genetics, Achillion, Catalyst Pharma
at The Street - Fri Oct 03, 8:41AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
JNJ: 108.20 (-0.81), SGEN: 36.05 (+1.20), CPRX: 2.73 (-0.09), ACHN: 10.11 (-0.15), SNSS: 1.63 (-0.05), BMY: 58.32 (-0.14)
